vietnam osteoporosis workshop, hcm cty 2006 secondary osteoporosis tuan van nguyen and nguyen dinh...
Post on 22-Dec-2015
213 views
TRANSCRIPT
Vietnam Osteoporosis Workshop, HCM Cty 2006
Secondary Osteoporosis
Tuan Van Nguyen and Nguyen Dinh NguyenBone and Mineral Research ProgramGarvan Institute of Medical Reseach
Sydney, Australia
Vietnam Osteoporosis Workshop, HCM Cty 2006
Overview
• Definitions
• Causes
• Corticosteroid Induced Osteoporosis:– Machanism– Magnitude of the problem– Patient managements
Vietnam Osteoporosis Workshop, HCM Cty 2006
Secondary osteoporosis
• Results from chronic conditions that contribute significantly to accelerated bone loss.
• Treatment of secondary osteoporosis is more complex than that of primary osteoporosis.
• Prognosis depends on the underlying disease.
Vietnam Osteoporosis Workshop, HCM Cty 2006
Secondary Osteoporosis
Endocrine or Metabolic causes
Medications
Collagen/genetics disorders
Nutritional disorders
Forms of secondary osteoporosis
Vietnam Osteoporosis Workshop, HCM Cty 2006
Endocrine or metabolic causes
• Hypogonadism• Hyperparathyroidism• Cushing-syndrome• Acidosis• Diabetes (type I)• Androgen insensitivity• Hemochromatosis• Gaucher’s disease
Vietnam Osteoporosis Workshop, HCM Cty 2006
Medications
• Corticosteroids
• Thyroid
• GnRH antagonists
• Anti-neoplastic agents
• Cyclosporin, methotrexate
• Phenobarbital
• Phenothiazines, Phenytoin
Vietnam Osteoporosis Workshop, HCM Cty 2006
Collagen/genetic disorders
• Ehler-Danlos syndrome
• Glycogen storage diseases
• Homocysturina
• Hypophosphatasis
• Marfan syndrome
• Osteogenesis Imperfecta
Vietnam Osteoporosis Workshop, HCM Cty 2006
Nutritional
• Alcoholism
• Calcium deficiency
• Chronic liver disease
• Gastric operations
• Malabsorption syndromes
• Vitamin D deficiency
Vietnam Osteoporosis Workshop, HCM Cty 2006
Corticosteroid-induced osteoporosis
• CS used in many underlying diseases
• Benefits effects on the underlying disease vs. detrimental effects on bone.
• High percentage of osteoporosis and fracture
• Dose-dependent effect difficult to define
Vietnam Osteoporosis Workshop, HCM Cty 2006
CIPO-Epidemiology
• Prevalence of use of oral corticosteroids:– Population: 0.5%– Among women aged ≥ 55: 1.7%
L J Walsh et al, BMJ 1996;313:344-6
• Main indications:– Rheumatoid arthritis– Polymyalgia– COPD
• 14% of patients taking any treatment of osteoporosis
Vietnam Osteoporosis Workshop, HCM Cty 2006
CIPO: Burden
• Most common of drug-related osteoporosis in men and women
• Occur at any age, in both sexes, across races• Up to 50% patient of chronic steroid therapy sustain
osteoporotic fractures and/or develop osteonecrosis.• Significant bone loss can occur in as little as 3
months.• 50% chance of developing osteoporosis if on steroid
for 6 mo.
Vietnam Osteoporosis Workshop, HCM Cty 2006
Corticosteroids-effect on bone
Corticosteroids
Osteoblast
Inhibition
enhancement
Bone resorptionCalcium loss
increase
Calcium absorption
InhibitionInhibition
Gonadal hormone
Vietnam Osteoporosis Workshop, HCM Cty 2006
Who is at high-risk of CIPO?
Eastell R et al, J Intern Med 1998;244:271-92 Tobias JH, Rheumatology 1999;38:198-201
- Prior fracture- Premature menaupause at < 45y- Age > 65 y- Planned or current use CS > 6 mo- Low weight- Other causes of Osteoporosis
Vietnam Osteoporosis Workshop, HCM Cty 2006
CIPO and fractureR
elat
ive
risk
of
frac
ture
com
par
ed t
o c
on
tro
ls
0
1
2
3
4
5
6Non-vertebral Hip Vertebrae Forearm
Low dose(< 2.5mg/d)
Medium dose(2.5-7.5mg/d)
High dose(>7.5mg/d)
(Source: van Staa TP et al., 2000)
Vietnam Osteoporosis Workshop, HCM Cty 2006
Patient assessment
Eastell R et al, J Intern Med 1998;244:271-92
BMD measurement
BMD-Tscores? High-risk of CIOP?
>1 0 to -1.5 < -1.5 or with CS >15mg/dor with CS 7.5mg/d
x 6mo
-Thoracic and lumbar spine X-ray
-FBC, ESR & S-Electrophoresis if necessary
-Serum Ca, P, AP, Albumin
-Thyroid function
-Men: testosterone an women: FSH, LH
In 3-5 y
After 1 y
Lifestylemodification advice:
-Smoking
-Alcohol
-Physical activity
-Prevent fall
Vietnam Osteoporosis Workshop, HCM Cty 2006
CIOP-Management
• Primary prevention, PP (treatment started at the time initiation up to 3 mo of CS therapy)
• Secondary prevention, SP (treatment started >1y after the time initiation of CS therapy)
Vietnam Osteoporosis Workshop, HCM Cty 2006
Pharmacological therapyAgent PP SP Dose
Calcium &Vit D v v 1000mg/d & 50000U/w
Calcitrol v NA 0.6µg/d
Alfacalcidiol v NA 1µg/d
Calcitonin v NA Conflicting results (200U/d, nasal)
Fluoride v v 25mg BID plus Calcium
Etidronate v v marginal effect
Alendronate v v 5mg/d
Pamidronate v v Intermittent IV
Risedronate v v 5mg/d
HRT NA v
Testosterone (men) NA v
Vietnam Osteoporosis Workshop, HCM Cty 2006
Key messages
• Secondary osteoporosis is common
• Patients on CS therapy should be consider the need for therapy to prevent or treat CIOP
• Data on CIOP fracture reduction with treatment remain sparse
Vietnam Osteoporosis Workshop, HCM Cty 2006
Lời Cảm tạ
• Chúng tôi xin chân thành cám ơn Công ty Dược phẩm Bridge Healthcare, Australia là nhà tài trợ cho hội thảo.